A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS
ConditionARDS
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorBonusBio Group Ltd
About this trial
The efficacy of the allogeneic cell-therapy product MesenCure in addition to standard of care will be evaluated in comparison to placebo control in 300 moderate to severe Covid patients
Eligibility criteria
Qualifiers
Patients are able and agree to sign informed consent form before any study-specific procedure.
Males or females, age range 18-80.
Documented ARDS
RA-O2 Saturation of ≤93% and/or Evidence of COVID19-related pulmonary infiltrates on chest X-ray/thoracic tomography
Disqualifiers
Pregnant or breast-feeding females.
History of drug abuse.
Heavy smokers (above 2 packages a day).
Subjects incapable of giving consent.
Trial design
Treatments tested in this trial
- MesenCure
- Placebo
Treatment groups
300 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov